Post-Market Clinical Follow-Up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in Patients With Type 1 and Type 2 Diabetes Mellitus

Enrolling by invitationOBSERVATIONAL
Enrollment

72

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

September 17, 2025

Study Completion Date

January 31, 2026

Conditions
Diabetes Mellitus
Interventions
DEVICE

CT3 Series Continuous Glucose Monitoring System:

The CT3 Series CGM System is a real-time, continuous glucose monitoring device indicated for the management of diabetes in adults (age≥18 years). Interpretation of the CT3 Series CGM System results should be based on the glucose trends and several sequential readings over time. The CT3 Series CGM System also aids in the detection of episodes of hyperglycaemia and hypoglycaemia. It is intended for single-patient use. It is intended to replace fingerstick blood glucose testing for diabetes treatment decisions unless otherwise indicated

Trial Locations (1)

LV1002

Paula Stradiņa klīniskā universitātes slimnīca, Riga

All Listed Sponsors
lead

MDCECRO LLC

NETWORK